Previous 10 | Next 10 |
Nautilus Biotechnology, Inc. (NAUT) Q3 2021 Earnings Conference Call November 2, 2021 08:30 ET Company Participants Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientific Officer Anna Mowry - Chief Financial Officer Conference Call Participant...
Cowen has initiated Nautilus Biotechnology (NAUT +10.5%) with an outperform rating citing the company's early success in "unlocking" the proteome which could help in development of treatments for diseases. The firm does not have a price target on shares. Analyst Max Masucci says that the risk...
Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome As an element of Nautilus' overall reagent development and sourcing strategy, the partnership aims to accelerate research and development, and provide customers with access to Abcam's ant...
Nautilus Biotechnology (NASDAQ:NAUT): Q3 GAAP EPS of -$0.12. Cash, cash equivalents, and investments were $374.0M as of September 30, 2021. For further details see: Nautilus Biotechnology reports Q3 results
SEATTLE, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today reported financial results for the third quarter ended September 30,...
The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....
SEATTLE, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter of ...
Growth and value equities have taken a hit in September, which is historically a terrible month for stocks, the politics of a shutdown and potential default look to be temporary headwinds. I am feeling very good at the moment regarding my positions and exposure to durable trends in th...
SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating virtually in the ...
Nautilus Biotechnology seeks to deliver on the untapped potential of the human proteome. The company debuted for public trade on Nasdaq Global Select Market on 6/10/2021. The company started off with gross proceeds of $345 million from the business combination with a SPAC. F...
News, Short Squeeze, Breakout and More Instantly...
Nautilus Biotechnology Inc. Company Name:
NAUT Stock Symbol:
NASDAQ Market:
Nautilus Biotechnology Inc. Website:
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. “In Q2, we saw con...
SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 3...
SEATTLE, May 23, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Goldman Sachs 45th Annual Healthcare Conference. Nauti...